Web28 jul. 2024 · IONIS-FXI Rx was the first anti-thrombotic in development to demonstrate potential to separate anti-thrombotic activity from bleeding risk. About the RE-THINC ESRD Study RE-THINC ESRD ( NCT04534114 ) is a randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics and pharmacodynamics of multiple doses … Web11 jul. 2024 · A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of IONIS FXI-LRx in up to 84 Healthy Volunteers View this study on Beta.ClinicalTrials.gov Sponsor: Ionis Pharmaceuticals, Inc. Information provided by (Responsible Party): Ionis Pharmaceuticals, Inc. Study Details …
Ionis
Web1 jul. 2024 · On the other hand, non-RNase H1-dependent ASOs can be designed to reduce target RNA levels via different mechanisms, including 1) acting on pre-mRNA and triggering alternative splicing, generating premature termination codon (PTC) containing mRNAs which are NMD targets; 2) acting on mature mRNA blocking translation, leading to reduced … WebIONIS-FXI RX is an antisense oligonucleotide inhibiting the synthesis of coagulation factor XI (FXI) that was clinically studied in healthy volunteers, patients who un- derwent total … hudson oak dining table
Antisense drug discovery and development technology considered …
Web1 feb. 2024 · IONIS-FXIRx was not associated with drug-related serious adverse events. In the randomized phase of the study, major bleeding events occurred in 0 (0.0%; 200 mg), … WebIONIS-MAPT Rx is being developed to treat people with Alzheimer’s disease (AD) and potentially other neurodegenerative disorders characterized by the deposition of abnormal tau protein in the brain, such as certain forms of … Web1 nov. 2016 · "IONIS-FXI Rx is a prime example of the power of antisense technology to selectively target a key component of the complex antithrombotic pathway that is not … hudson yang 2022